alfimeprase

TERMINATED · PHASE3 · Arterial Occlusive Diseases

Based upon preliminary safety and efficacy results from a similar study.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.